Ipilimumab (IPI) vs placebo (PBO) after complete resection of stage III melanoma: final overall survival results from the EORTC 18071 randomized, double-blind, phase 3 trial

被引：2

作者：

Eggermont, A. M. M. ^{[1
]}

Chiarion-Sileni, V. ^{[2
]}

Grob, J-J. ^{[3
]}

Dummer, R. ^{[4
]}

Wolchok, J. D. ^{[5
]}

Schmidt, H. ^{[6
]}

Hamid, O. ^{[7
]}

Robert, C. ^{[8
]}

Ascierto, P. A. ^{[9
]}

Richards, J. M. ^{[10
]}

Lebbe, C. ^{[11
,12
]}

Ferraresi, V. ^{[13
]}

Smylie, M. ^{[14
]}

Weber, J. S. ^{[15
]}

Taitt, C. ^{[16
]}

de Pril, V. ^{[17
]}

de Schaetzen, G. ^{[18
,19
]}

Suciu, S. ^{[18
,19
]}

Testori, A. ^{[20
]}

机构：

[1] Gustave Roussy Canc Campus Grand Paris, Oncol Surg, Villejuif, France

[2] IRCCS, IOV, Dept Dermatol, Melanoma Oncol Unit, Padua, Italy

[3] Aix Marseille Univ, Hop La Timone APHM, Dept Dermatol & Skin Canc, Marseille, France

[4] Univ Zurich Hosp, Dept Dermatol, Zurich, Switzerland

[5] Mem Sloan Kettering Canc Ctr, Melanoma & Immunotherapeut Serv, 1275 York Ave, New York, NY 10021 USA

[6] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark

[7] Angeles Clin & Res Inst, Clin Res, Los Angeles, CA USA

[8] Gustave Roussy Canc Campus Grand Paris, Dermatol Unit, Villejuif, France

[9] Fdn G Pascale, Ist Nazl Tumori, Melanoma Canc Immunotherapy & Innovat Therapy Uni, Naples, Italy

[10] Oncol Specialists SC, Div Hematol Oncol, Park Ridge, IL USA

[11] Univ Paris 07, INSERM, U976, Hop St Louis,APHP,Dept Dermatol, Paris, France

[12] Univ Paris 07, INSERM, U976, Hop St Louis,APHP,CIC Dept, Paris, France

[13] Ist Fisioterapici Ospitalieri, Dept Med Oncol, Rome, Italy

[14] Cross Canc Inst, Dept Oncol, Edmonton, AB, Canada

[15] H Lee Moffitt Canc Ctr & Res Inst, Dept Med, Tampa, FL USA

[16] Bristol Myers Squibb, Worldwide Med, Princeton, NJ USA

[17] Bristol Myers Squibb, Worldwide Med, Braine Lalleud, Belgium

[18] EORTC Headquarters, Melanoma Grp, Brussels, Belgium

[19] EORTC Headquarters, Melanoma Grp, Brussels, Belgium

[20] European Inst Oncol, Div Melanoma & Sarcomi Muscolocutanei, Milan, Italy

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw435.35

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA2_PR

引用

页数：1

共 50 条

[21] Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED)
Schadendorf, D.
Hassel, J. C.
Fluck, M.
Eigentler, T.
Loquai, C.
Berneburg, M.
Gutzmer, R.
Meier, F.
Mohr, P.
Hauschild, A.
Becker, J. C.
Menzer, C.
Kiecker, F.
Dippel, E.
Simon, J-C.
Conrad, B.
Garbe, C.
Koerner, S.
Livingstone, E.
Zimmer, L.
ANNALS OF ONCOLOGY, 2019, 30
[22] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
Eggermont, Alexander M.
Blank, Christian U.
Mandala, Mario
Long, Georgina V.
Atkinson, Victoria
Dalle, Stephane
Haydon, Andrew
Lichinitser, Mikhail
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Maio, Michele
van den Eertwegh, Alfonsus J.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Rivas, Veronica
Ibrahim, Nageatte
Marreaud, Sandrine
Janssen, Sven
van Akkooi, Alexander
Suciu, Stefan
Robert, Caroline
CANCER RESEARCH, 2018, 78 (13)
[23] Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).
Sternberg, Cora N.
Fizazi, Karim
Saad, Fred
Shore, Neal D.
De Giorgi, Ugo
Penson, David F.
Ferreira, Ubirajara
Ivashchenko, Petro
Efstathiou, Eleni
Madziarska, Katarzyna
Kolinsky, Michael Paul
Cubero, Daniel Iracema
Noerby, Bettina
Zohren, Fabian
Lin, Xun
Modelska, Katharina
Sugg, Jennifer
Steinberg, Joyce Leta
Hussain, Maha H. A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[24] Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Eggermont, Alexander M. M.
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Giacomo, Anna Maria Di
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Lorigan, Paul C.
van Akkooi, Alexander C. J.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
LANCET ONCOLOGY, 2021, 22 (05): : 643 - 654
[25] Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial
Wallack, MK
Sivanandham, M
Balch, CM
Urist, MM
Bland, KI
Murray, D
Robinson, WA
Flaherty, L
Richards, JM
Bartolucci, AA
Rosen, L
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 187 (01) : 69 - 77
[26] Everolimus (EVE) for Advanced, Progressive Pancreatic Neuroendocrine Tumors (pNET): Final Overall Survival (OS) from a Randomized, Double-Blind, Placebo (PBO)-Controlled, Multicenter Phase 3 RADIANT-3 Study
Yao, J. C.
Pavel, M.
Lombard-Bohas, C.
Van Cutsem, E.
Lam, D.
Kunz, T.
Brandt, U.
Capdevila, J.
De Vries, E.
Tomassetti, P.
Hobday, T.
Pommier, R.
NEUROENDOCRINOLOGY, 2015, 102 (1-2) : 134 - 134
[27] Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma
Khattak, A.
Robert, C.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V.
Dalle, S.
Haydon, A.
Lichinitser, M.
Carlino, M. S.
Sandhu, S.
Larkin, J.
Puig, S.
Ascierto, P. A.
Rutkowski, P.
Schadendorf, D.
Lorigan, P.
Ibrahim, N.
Suciu, S.
Eggermont, A. M. M.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 48 - 48
[28] Adjuvant nivolumab plus ipilimumab (NIVO plus IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial
Motzer, R. J.
Russo, P.
Gruenwald, V.
Tomita, Y.
Zurawski, B.
Parikh, O. A.
Buti, S.
Barthelemy, P.
Goh, J. C. H.
Ye, D.
Lingua, A.
Lattouf, J-B.
Escudier, B.
George, S.
Shuch, B.
Simsek, B.
Spiridigliozzi, J.
Chudnovsky, A.
Bex, A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1430 - S1430
[29] Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients with advanced melanoma (CheckMate 067)
Larkin, James
Chiarion-Sileni, Vanna
Gonzalez, Rene
Rutkowski, Piotr
Grob, Jean-Jacques
Cowey, C. Lance
Lao, Christopher D.
Schadendorf, Dirk
Ferrucci, Pier Francesco
Smylie, Michael
Dummer, Reinhard
Hill, Andrew
Haanen, John
Maio, Michele
McArthur, Grant
Walker, Dana
Rollin, Linda
Horak, Christine
Hodi, F. Stephen
Wolchok, Jedd D.
CANCER RESEARCH, 2017, 77
[30] Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial
Zimmer, Lisa
Livingstone, Elisabeth
Hassel, Jessica C.
Fluck, Michael
Eigentler, Thomas
Loquai, Carmen
Haferkamp, Sebastian
Gutzmer, Ralf
Meier, Friedegund
Mohr, Peter
Hauschild, Axel
Schilling, Bastian
Menzer, Christian
Kieker, Felix
Dippel, Edgar
Rosch, Alexander
Simon, Jan-Christoph
Conrad, Beate
Korner, Silvia
Windemuth-Kieselbach, Christine
Schwarz, Leonora
Garbe, Claus
Becker, Juergen C.
Schadendorf, Dirk
LANCET, 2022, 400 (10358): : 1117 - 1129

← 1 2 3 4 5 →